首页> 外文期刊>Hematology. >Comparison of cost effectiveness between measuring the serum erythropoietin level and reticulocyte count for monitoring thalassemic patients: a note in Thai beta thalassemia/Hb E subjects.
【24h】

Comparison of cost effectiveness between measuring the serum erythropoietin level and reticulocyte count for monitoring thalassemic patients: a note in Thai beta thalassemia/Hb E subjects.

机译:测量血清促红细胞生成素水平和网状细胞计数以监测地中海贫血患者的成本效益比较:泰国β地中海贫血/ Hb E受试者的一项注意事项。

获取原文
获取原文并翻译 | 示例
           

摘要

Iron deficiency anaemia and the thalassemia syndromes, a group of disorders resulting from inherited abnormality of globin chain production, are common causes of anaemia in Thailand, and in the Far East in general. Monitoring erythropoiesis in these patient is very important in evaluating the disease and the response to treatment. Recently, our group has just reported the feasibility in using serum erythropoietin (EPO) for monitoring purposes in thalassemia and demonstrated that the determination of serum EPO can be an alternative choice in the follow up of these conditions. This study reports a cost effectiveness analysis comparing the recently reported radioimmunoassay (RIA) for serum EPO determination and the previously used tool, the reticulocyte count. The study reports a higher detection rate for ineffective erythropoiesis when using serum EPO determination, however, the increased sensitivity is at balanced by a higher unit cost. In this analysis, the cost effectiveness for serum EPO and reticulocyte are 208.33 and 50 baht/detection, respectively. () Therefore, the reticulocyte count is more cost effective and is recommended for routine usage in our current medico-economic setting.
机译:缺铁性贫血和地中海贫血综合征是由遗传性珠蛋白链产生的遗传异常引起的一组疾病,是泰国和整个远东地区常见的贫血原因。监测这些患者的红细胞生成对评估疾病和对治疗的反应非常重要。最近,我们小组刚刚报道了在地中海贫血中使用血清促红细胞生成素(EPO)进行监测的可行性,并证明了在这些情况的随访中测定血清EPO可以作为替代选择。这项研究报告了成本效益分析,将最近报道的用于血清EPO测定的放射免疫测定(RIA)与以前使用的工具网织红细胞计数进行了比较。该研究报道,使用血清EPO测定时,无效红细胞生成的检出率更高,但是,灵敏度的提高与较高的单位成本相平衡。在此分析中,血清EPO和网织红细胞的成本效益分别为208.33和50泰铢/检测。 ()因此,网织红细胞计数更具成本效益,建议在我们当前的药物经济环境中常规使用。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号